James Cochran
Urology · Dallas, TXNPI 1174577704
Payments from drug & device makers
Across 240 payments — averaging $4736.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$640K
- Bayer$127K
- Astellas Pharma Global Development$87K
- Urovant Sciences Inc$77K
- AbbVie$61K
- Pfizer$33K
- plus $111K from 30 others
Across 1 payment — averaging $72.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$73
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,136,692 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Homa PorterDallas$1.8M
- Vitaly MargulisDallas$1.8M
- Solomon WolduDallas$1.2M
- Yair LotanDallas$1.1M
- Allen MoreyDallas$1M
- Claus RoehrbornDallas$292K
- Brett JohnsonDallas$175K
- Pat FulghamDallas$174K
- Gregory ThoresonDallas$162K
- Zvi SchiffmanHouston$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.